{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Scleroderma+of+Lung&page=2",
    "query": {
      "condition": "Scleroderma of Lung",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Scleroderma+of+Lung&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T12:17:24.712Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06329401",
      "title": "A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Fibrosis",
        "Progressive Pulmonary Fibrosis",
        "Pulmonary Fibrosis Secondary to Systemic Sclerosis",
        "Pulmonary Fibrosis, Interstitial Lung Disease",
        "Interstitial Lung Disease",
        "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)",
        "Interstitial Lung Disease in Patients With Rheumatoid Arthritis",
        "Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere",
        "Hypersensitivity Pneumonitis",
        "Interstitial Lung Disease With Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "AP01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Avalyn Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 375,
      "start_date": "2024-04-03",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06329401"
    },
    {
      "nct_id": "NCT04837131",
      "title": "A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Sclerosis",
        "Scleroderma",
        "Diffuse Systemic Sclerosis",
        "Diffuse Scleroderma",
        "Diffuse Cutaneous Systemic Sclerosis",
        "Diffuse Cutaneous Scleroderma",
        "Progressive Systemic Sclerosis",
        "Progressive Scleroderma",
        "Scleroderma, Systemic",
        "Scleroderma, Diffuse",
        "Scleroderma;Progressive",
        "Systemic Sclerosis, Diffuse",
        "Systemic; Sclerosis, Progressive",
        "Scleroderma of Lung",
        "Scleroderma With Pulmonary Involvement",
        "Systemic Sclerosis Pulmonary",
        "Systemic Sclerosis With Lung Involvement",
        "Interstitial Lung Disease",
        "Pulmonary Fibrosis Interstitial"
      ],
      "interventions": [
        {
          "name": "Ixazomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael M. Pham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-04-28",
      "completion_date": "2024-02-23",
      "has_results": true,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04837131"
    },
    {
      "nct_id": "NCT00706082",
      "title": "Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Sclerosis",
        "Pulmonary Arterial Hypertension",
        "Pulmonary Hypertension"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2008-10",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2012-06-25",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00706082"
    },
    {
      "nct_id": "NCT05892614",
      "title": "Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "efzofitimod 450 mg",
          "type": "DRUG"
        },
        {
          "name": "efzofitimod 270 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2023-10-26",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-07",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Diego, California • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05892614"
    },
    {
      "nct_id": "NCT05878717",
      "title": "A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Systemic Sclerosis Associated Interstitial Lung Disease",
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2023-09-13",
      "completion_date": "2029-07-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 24,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05878717"
    },
    {
      "nct_id": "NCT03313180",
      "title": "A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases, Interstitial"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 444,
      "start_date": "2017-11-27",
      "completion_date": "2023-01-25",
      "has_results": true,
      "last_update_posted_date": "2024-02-20",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 39,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03313180"
    },
    {
      "nct_id": "NCT05559580",
      "title": "A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Avenciguat (BI 685509)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 214,
      "start_date": "2022-12-13",
      "completion_date": "2026-01-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Covina, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Covina",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05559580"
    },
    {
      "nct_id": "NCT05455437",
      "title": "Monitoring and Evaluation Study of Project ECHO for ILD",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Interstitial Lung Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pulmonary Care and Research Collaborative Limited",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 200,
      "start_date": "2022-07",
      "completion_date": "2024-03",
      "has_results": false,
      "last_update_posted_date": "2022-07-13",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05455437"
    },
    {
      "nct_id": "NCT06025578",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Progressive Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "BMS-986278",
          "type": "DRUG"
        },
        {
          "name": "BMS-986278 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 1057,
      "start_date": "2023-10-25",
      "completion_date": "2027-12-27",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06025578"
    },
    {
      "nct_id": "NCT02597933",
      "title": "A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Scleroderma, Systemic"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 580,
      "start_date": "2015-11-12",
      "completion_date": "2018-11-28",
      "has_results": true,
      "last_update_posted_date": "2019-12-13",
      "last_synced_at": "2026-07-23T12:17:24.712Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02597933"
    }
  ]
}